Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
Crossref DOI link: https://doi.org/10.1007/s40273-017-0557-6
Published Online: 2017-08-09
Published Print: 2018-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ansaripour, Amir http://orcid.org/0000-0002-9298-6393
Uyl-de Groot, Carin A.
Redekop, W. Ken
License valid from 2017-08-09
